With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
Uncontrolled diabetes in pregnancy dramatically increases the risk of pre-eclampsia, stillbirth, birth injuries, and long-term cardiometabolic diseases
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Total income for the period stood at Rs. 7101.28 crore
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
The investment in land is Rs. 19.85 crore
The observations are procedural in nature and will be responded to within the stipulated time
Fenebrutinib targets cells in the immune system known as B cells and microglia
Subscribe To Our Newsletter & Stay Updated
